Kodiak Sciences Q2 FY26 net loss widens to $65.64 million

KOD•2026-08-13

Second-quarter results and expenses

Kodiak Sciences posted a GAAP net loss of $65.6 million, or $1.05 a share, for the second quarter ended June 30, 2026.

R&D expense climbed 31% year over year to $56.1 million, on higher PEAK/PINNACLE clinical activity and Phase 3 manufacturing.

Cash position and clinical milestones

Cash and cash equivalents fell to $125.9 million at quarter-end; operations are expected to be funded into 2027.

Phase 3 DAYBREAK topline results for Zenkuda and KSI-501 in treatment-naïve wet AMD are expected in September 2026.

Phase 3 PEAK Pivotal Analysis 1 topline results for KSI-101 in MESI are expected in December 2026; Phase 3 ALTO in DME has begun enrolling.

Kodiak Sciences Q2 FY26 net loss widens to $65.64 million

Second-quarter results and expenses

Cash position and clinical milestones

Related News

Envista files Form 3 for CAO Coree K. Thomas initial beneficial ownership statement

Keystone Acquisition Q2 net income rises to $74,031; 6-month net income climbs to $36,791

Miluna Acquisition Q2 FY26 net income swings to $93,409

Wyndham Hotels & Resorts declares quarterly cash dividend of $0.43 per share

Turnongreen Q2 FY26 net loss narrows 47% to $348,000; revenue rises 4% to $1.75 million